Modeling the economic outcomes of immuno-oncology drugs: alternative model frameworks to capture clinical outcomes

BACKGROUND: Economic models in oncology are commonly based on the three-state partitioned survival model (PSM) distinguishing between progression-free and progressive states. However, the heterogeneity of responses observed in immuno-oncology (I-O) suggests that new approaches may be appropriate to...

Descripción completa

Detalles Bibliográficos
Autores principales: Gibson, EJ, Begum, N, Koblbauer, I, Dranitsaris, G, Liew, D, McEwan, P, Tahami Monfared, AA, Yuan, Y, Juarez-Garcia, A, Tyas, D, Lees, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5848668/
https://www.ncbi.nlm.nih.gov/pubmed/29563820
http://dx.doi.org/10.2147/CEOR.S144208

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5848668/
https://www.ncbi.nlm.nih.gov/pubmed/29563820
http://dx.doi.org/10.2147/CEOR.S144208

Ejemplares similares